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Introduction
Over the past 3 decades, a distinct protein has been found 
to accumulate in the brains of patients suffering from each of 
the neurodegenerative diseases. Mutations have been found 
in the respective genes encoding the particular etiologic pro-
teins responsible for the familial forms of the neurodegenera-
tive diseases. Increasing evidence argues that each of the 
disease-causing  proteins  undergo  posttranslational  modifi-
cation in a self-perpetuating process. This prion-like mech-
anism leads to the accumulation of the modified, etiologic 
proteins. In Creutzfeldt–Jakob disease of humans, scrapie 
of  sheep,  bovine  spongiform  encephalopathy,  and  chronic 
wasting disease, the cellular prion protein (PrPC) undergoes 
refolding into the disease-causing isoform (PrPSc). The pro-
gressive accumulation of PrPSc in the brain leads to central 
nervous system (CNS) dysfunction that is accompanied by 
neuronal vacuolation and astrocytic gliosis. In some cases, 
amyloid  plaques  composed  of  PrPSc  are  found  within  the 
CNS but such plaques are not an obligatory feature of these 
disorders.
Many lines of evidence converged to argue that PrPSc is 
the  sole  component  of  the  infectious  prion  particle.  Later, 
knockout of the PrP gene encoding PrPC was found to ren-
der mice resistant to experimental scrapie. This finding sug-
gested  that  patients  dying  of  Creutzfeldt–Jakob  disease 
would benefit from therapeutics that lower the levels of PrPC 
and/or PrPSc. Both RNA interference (RNAi) and antisense 
oligonucleotides (ASOs) have been used to lower the levels 
of PrPC and PrPSc in scrapie-infected cultured cells (ScN2a). 
RNAi molecules have been found to lower PrP mRNA levels 
and hence PrPC.1–4 In ScN2a cells as well as in the brains of 
scrapie-infected mice, the levels of PrPSc were also lowered 
by exposure to sequence-specific RNAi molecules. In con-
trast to the RNAi results, ASOs are confounded by the ability 
of these polymers to lower PrPSc levels in ScN2a indepen-
dent of their sequence.5,6
Treatment of prion diseases using transgenic (Tg) mice   
with  inducible  PrPC  expression  systems  have  been  per-
formed.7,8 Tg(NFH-Cre/MloxP)  mice  were  inoculated  with 
the Rocky Mountain Laboratory (RML) prions at 3–4 weeks 
of age.7 Cre-mediated recombination at 10–12 weeks of age 
was effectively used to suppress neuronal PrPC expression 
but not that in other CNS cells. Shutting off PrPC expression in 
neurons, even after mice developed signs of neurologic dys-
function, reversed spongiform degeneration and prevented 
clinical disease. Surprisingly, mice remained asymptomatic 
even  though  their  brains  were  inundated  with  extraneu-
ronal PrPSc deposits. In bigenic Tg(tTA:PrP+/0)3 mice, PrPC 
expression was regulated by oral doxycycline administra-
tion.8 PrPC expression was reduced by 95% in the brains of 
bigenic mice compared to wild-type mice, which extended 
survival times following prion inoculation from ~150 to ~430 
days when the mice eventually developed clinical disease. 
In these mice, PrPC suppression prevented pyramidal nerve 
cell death and enhanced the clearance of PrPSc deposits. 
Recently, a single injection of small hairpin RNA targeting 
PrP into the hippocampus of Tg37 mice protected the thala-
mus and cortex, brain regions distal to the injection site, 
from prion-induced neurodegeneration and prolonged sur-
vival time from 85 to 105 days even though PrPC expression 
was reduced only at the   border of the injection site.4
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Mice deficient for the cellular prion protein (PrPC) do not develop prion disease; accordingly, gene-based strategies to diminish 
PrPC expression are of interest. We synthesized a series of chemically modified antisense oligonucleotides (ASOs) targeted 
against mouse Prnp messenger RNA (mRNA) and identified those that were most effective in decreasing PrPC expression. Those 
ASOs were also evaluated in scrapie-infected cultured cells (ScN2a) for their efficacy in diminishing the levels of the disease-
causing prion protein (PrPSc). When the optimal ASO was infused intracerebrally into FVB mice over a 14-day period beginning 
1 day after infection with the Rocky Mountain Laboratory (RML) strain of mouse prions, a prolongation of the incubation period 
of almost 2 months was observed. Whether ASOs can be used to develop an effective therapy for patients dying of Creutzfeldt–
Jakob disease remains to be established.
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Figure 1  Identification of ASOs that diminish mouse Prnp mRNA expression measured by qRT-PCR. (a) Experimental design.   
(b) Prnp mRNA expression 24 hours post-transfection with 78 antisense oligonucleotides (120 nmol/l) targeting mouse Prnp mRNA in 
b.END cells. ASOs are displayed relative to their position on the 2,206-bp mouse Prnp mRNA (Accession NM_011170). (c) Dose-response 
of Prnp mRNA expression using the 10 most-effective ASOs in b.END cells. ASO concentrations ranged from 6.25–200 nmol/l, as indi-
cated. Prnp mRNA is expressed as a percentage compared to untransfected control (UTC). ASO, antisense oligonucleotide; bp, base pair; 
ICV, intracerebral ventricular; mRNA, messenger RNA; qRT-PCR, quantitative real time-PCR.www.moleculartherapy.org
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Several clinically desirable advantages over lentiviral injec-
tions of RNAi molecules are offered by the intracerebral ven-
tricular (ICV) delivery of ASOs that are fully phosphorothioated 
(PS). The five base caps at each end of the 20mer ASO were 
methoxyethyl-modified to increase potency and stability as 
well as to decrease proinflammatory effects. The PS modi-
fication in the backbone of DNA, in which one non-bridging 
oxygen atom is replaced with a sulfur atom, increases nucle-
ase resistance, resulting in enhanced stability both in vitro 
and in vivo. In addition, the PS modification improves tissue 
distribution and cell uptake in vivo. The methoxyethyl modi-
fication increases the affinity of the ASOs for RNA and pro-
tects the 20mer from exonuclease degradation, resulting in an 
extended duration of action in tissues due to a longer meta-
bolic half-life.9 Once introduced into the cells, hybridization of 
the ASO to the target mRNA results in RNase H cleavage of 
the message and suppression of gene expression.10
Here, we report on ASOs targeting mouse Prnp mRNA that 
suppress PrPC expression and inhibit PrPSc formation in cell 
culture and scrapie-infected mice. Intraventricular infusion of 
an ASO, for 14 days beginning 1 day after inoculation with 
RML prions, extended incubation periods in prion-infected 
mice by almost 2 months.
Results
Strategy. We synthesized and screened 78 ASOs with meth-
oxyethyl  gapmer  chemistry  targeting  the  mouse  (Mo)  PrP 
message in a mouse endothelial cell line designated b.END. 
From this panel, we identified the 10 most active ASOs for 
PrP transcript knockdown by dose response. The three most-
effective ASOs—742, 747, and 771—were then screened for 
efficacy in reducing PrPC and PrPSc in N2a and ScN2a cells, 
respectively. These three ASOs were injected intraperitoneally 
(ip) in uninfected FVB mice to evaluate tolerance as well as 
to verify in vivo transcript and protein knockdown in the liver. 
Next, the three ASOs were tested for RNA and protein knock-
down in the brain by intracerebral administration into the left 
lateral ventricle through a cannula using an implanted Alzet 
osmotic pump. Of the three most effective ASOs, 771 was 
chosen for further study in scrapie-infected mice (Figure 1a).
In vitro screening. High-throughput screening of 78 ASOs 
by quantitative real-time (qRT) PCR identified the 10 with the 
greatest mRNA knockdown efficacy (Figure 1b). These 10 
ASOs were then evaluated by measuring the dose-  dependent 
responses in b.END cells; ASOs were added at increasing 
concentrations (6.5–200 nmol/l) in the presence of the lipo-
fectamine transfection reagent (Figure 1c). ASOs 742, 747, 
and 771 had the greatest potency, with PrP mRNA levels 
reduced by 94, 97, and 97%, respectively, at the 200-nmol/l 
dose compared to cells treated with non–sequence-specific 
control ASO 923 (Table 1).
Based on reductions in PrP mRNA levels in b.END cells, 
ASOs 742, 747, and 771 were screened in N2a cells. These 
ASOs target three sites in the 3′ untranslated region (UTR) 
of MoPrP mRNA (NM_011170.1; Figure 2a). Furthermore, 
this experimental scenario better mimics in vivo delivery of 
the drug into the brain. Cells were cultured for 30 days in the 
continuous presence of 500 nmol/l of each ASO and lysates 
were collected at 2, 7, 14, and 28 days for analysis of PrPC 
expression by western immunoblots, which were quantified 
by densitometry (Figure 2b). ASO 771 reduced PrPC levels 
more rapidly than the other two ASOs, with a 60% reduction 
observed following 7 days of exposure and 84% reduction 
by  14  days.  Control  ASO  923  elicited  low  levels  of  non–
sequence-specific reduction of PrPC expression, by ~20% at 
7, 14, and 28 days.
Antisense inhibition of PrP 27-30 in ScN2a cells. To deter-
mine whether ASO-mediated PrPC suppression affects PrPSc 
levels in prion-infected cells, ScN2a cells were cultured in the 
presence of 500 nmol/l of each lead ASO and lysates col-
lected at 2, 7, 14, and 28 days. Following 2 days of treatment, 
levels of PrP 27-30, the protease-resistant core of PrPSc, were 
reduced by 81% with ASO 742, by 63% with ASO 747, and by 
57% with ASO 771 (Figure 2c). After 7 days of exposure to 
ASOs 742, 747, or 771, PrP 27-30 was not detectable. Cells 
exposed to the control ASO 923 for 2 days showed a 41% 
reduction in PrP 27-30, and a 95% reduction in PrP 27-30 
after  7  days. We  and  others  had  previously  reported  the 
reduction in PrPSc levels by sequence-scrambled PS oligonu-
cleotides.5,6 Following 28 days of exposure to each of the four 
ASOs including the control ASO 923, PrPSc was undetect-
able. To determine whether these observations were specific 
to ScN2a cells, these experiments were also performed with 
prion-infected GT1 cells, ScGT1. PrP 27-30 in this cell line 
was completely eliminated after 7 days of exposure to each 
of ASOs including the control ASO 923 (data not shown).
To determine the ASO 771 concentration at which PrPC 
and  PrPSc  levels  were  suppressed  by  50%  (half  maximal 
effective concentration (EC50)) in N2a and ScN2a cells, we 
treated cells with ASO 771 at concentrations ranging from 2 
to 250 nmol/l, collected lysates after 7 days, then measured 
PrPC and PrPSc levels by western blot. Increasing ASO con-
centrations reduced the level of PrP 27-30 in ScN2a cells 
in an exponential manner (Figure 2d). The EC50 values for 
ASO 771 were 50 nmol/l for PrPC and 4 nmol/l for PrPSc. The 
control ASO 923 had an EC50 of 10 nmol/l for PrPSc due to 
non–sequence-specific effects (Figure 2c). It is noteworthy 
that ASO 771 was only able to reduce PrPC levels by 60% 
in  cultured  N2a  cells  at  a  concentration  above  50  nnol/l 
 ( Figure 2d). This reduction was sequence-specific in con-
trast to the reduction of PrPSc, which exceeded 95% with less 
than 10 nmol/l of ASO 771.
Table 1  Percentage inhibition of Prnp mRNA expression in mouse b.END cells 
by different doses of ASOs compared to control cells treated with ASO 923
mRNA inhibition (%)
Dose (nmol/l) ASO 742 ASO 747 ASO 771
6.25 41 34 28
12.5 57 53 48
25 79 82 73
50 86 95 91
100 93 98 95
200 94 97 97
Abbreviations: ASO, antisense oligonucleotide; mRNA, messenger RNA; 
PBS, phosphate-buffered saline.Molecular Therapy–Nucleic Acids
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ASOs reduced PrPC levels in vivo. Based on our findings 
in cell culture, we investigated whether ASOs 742, 747, and 
771  would  be  well-tolerated  and  effective  in  diminishing 
mRNA and PrPC levels in vivo. We administered each ASO 
to eight groups of five FVB mice for 21 days via ip injec-
tions.  Phosphate-buffered  saline  (PBS)  and  control  ASO 
847,  which  targets  PTEN  protein,  were  used  as  controls. 
The ASOs and PBS were administered ip twice weekly for 
3 weeks, in doses of either 50 mg/kg/week or 100 mg/kg/
week (Figure 3a). None of the mice showed negative effects 
through the course of ASO administration. All of the animals 
remained healthy until they were killed at 21 days. Routine 
clinical serum chemistry was performed and no abnormali-
ties were observed (data not shown).
Prnp mRNA expression in liver was determined by qRT-
PCR;  PrPC  expression  was  measured  by  enzyme-linked 
immunosorbent  assay  (ELISA)  using  anti-PrP  HuM-Fab 
D18 for detection. The greatest Prnp mRNA and PrPC dimi-
nutions in liver were found with the ASO 742: on 50 or 100 
mg/kg/week,  respective  reductions  of  75  and  85%  in  PrP 
mRNA (Figure 3b), and of 65 and 72% in PrPC, were found 
 ( Figure 3c). ASO 771 at 50 mg/kg/week reduced Prnp mRNA 
by 30% and PrPC by ~50% in liver, as measured by qRT-PCR 
and immunoblotting, respectively.
Intracerebral ventricular delivery of ASOs reduced brain 
PrPC. Encouraged  by  the  safety  profile  and  the  effective 
reduction of PrPC by the ASOs in liver following systemic 
administration,  we  next  characterized  the  tolerability  and 
pharmacology of ASOs in the CNS via intracerebral ventricu-
lar (ICV) administration (Figure 3d). Two lead ASOs 771 and 
742 were continuously infused into the right lateral ventricle 
(Figure  3e,  region  3)  of  FVB  mice  using  implanted  Alzet 
osmotic pumps, at a dose of 75 µg/day for 21 days, after 
which mice were killed within 24 hours. A control group of 
mice was treated with PBS in the same manner for the same 
time period. The ASOs were well-tolerated; neither toxic side 
effects nor brain abscesses were observed. Histopathologi-
cal analysis of a section of the midbrain, posterior to the can-
nulation site, showed no abnormalities (data not shown).
mRNA and PrPC levels were evaluated using different brain 
regions. RNA was isolated from a portion of brain adjacent to 
the cannulated lateral ventricle and ventral to the cannulation 
site (Figure 3e, region 2). For PrPC, a portion of the brain ante-
rior to and on the ipsilateral side of cannulation (Figure 3e, 
region 1) was homogenized in PBS (10% w/v) and analyzed by 
densitometry of western blots. PrP mRNA measured by qRT-
PCR was ~60% lower in mice receiving either ASO 742 or 771 
compared to mice infused with PBS (Figure 3f). Administration 
of ASO 742 and 771 resulted in 30% and ~70% less PrPC, 
respectively, in the brain compared to mice receiving PBS con-
trol injections as shown by immunoblotting (Figure 3g,h).
Next, we conducted a dose-response study to determine 
the potency and tolerable dose compared to our previous, 
single-dose  study  for  which  75  µg  was  administered  per 
Figure 2  ASOs targeting mouse Prnp mRNA reduced PrPC 
and PrPSc expression in N2a and ScN2a cells.  (a) The three 
lead ASOs 742, 747, and 771 identified in b.END cells are dis-
played  relative  to  their  positions  on  the  2,206-bp  mouse  Prnp 
mRNA   (Accession NM_011170). All fall within exon 4 outside of 
the coding sequence in the 3′ UTR. (b,c) Kinetics of PrPC sup-
pression in N2a cells is shown in b and protease-resistant PrPSc in 
ScN2a cells is shown in c exposed to 500 nmol/l of each ASO for 
2, 7, 14, and 28 days. ASO 923 and PBS were used as controls.   
(d) Dose-response curves of PrPC in N2a and PrPSc in ScN2a cells 
incubated with 0–250 nmol/l of ASO 771. In b–d, PrP levels were 
quantified by densitometry of scanned western blot films   using NIH 
Image J software and expressed as percentages relative to cells 
treated with PBS. Protein standards shown are 36, 30, and 22 kilo-
daltons. ASO, antisense oligonucleotide; mRNA, messenger RNA; 
ORF, open reading frame; PBS, phosphate-buffered saline; PrPC, 
cellular prion protein; PrPSc, disease-causing prion protein.
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day. ASO 742 and 771, at doses of 25, 50, 75 and 100 µg/
day, were continuously infused via ICV into the right lateral 
ventricle for 14 days (Figure 4a). A control group of mice 
received PBS via ICV delivery for the same time period. Mice 
were killed 24 hours after the end of the infusion. With the 
exception of 100 µg/day of ASO 742, all other doses were 
well-tolerated by the mice.
PrP mRNA levels were analyzed in a brain section poste-
rior to the cannulation site (Figure 3e, region 2) by   qRT-PCR 
(Figure  4b).  PrP  mRNA  expression  levels  decreased  in 
an ASO dose-dependent manner. Delivery of ASO 742 at   
50 µg/day reduced PrP mRNA levels by ~60% while ASO 
771 at 100 µg/day decreased PrP mRNA by 70%.
Histoblots of coronal cryosections showed that PrPC sup-
pression was most marked on the cannulated side of the 
brain, but was also found on the contralateral side (Figure 4c).   
Mice infused with ASO 771 at 75 µg/day showed the most 
pronounced decrease in PrPC expression compared to those 
receiving PBS. A midbrain section (Bregma −2.92 mm) taken 
from a mouse treated with 75 µg/day of ASO 771 was fixed 
and stained with the ASO antibody (Figure 4d, brown stain-
ing). The ASO dispersed from the injection site, travelling a 
distance of 2.92 mm Bregma to the midbrain and penetrated 
neurons bilaterally. Together, these results demonstrate that 
ASO 771 administered in vivo to the brain by ICV infusion is 
well-tolerated and reduces both Prnp mRNA and PrPC.
ASO 771 treatment of prion-inoculated mice. On day 0, 
mice were inoculated on the right side of the brain with 
RML prions. The next day, ICV infusion of ASO 771 (75 
µg/d) or PBS was initiated on the left side of the brain and 
continued for 14 days. At 50 dpi (36 days after ICV treat-
ment ended), six mice (three from the treated group and 
three from the control group) were killed in order to mea-
sure the levels of PrPC and PrPSc (Figure 5). Another group 
of mice (eight from the treatment group and six controls) 
were observed until they developed signs of neurological 
dysfunction (Figure 6).
In mice killed at 50 dpi, histoblots showed that ASO 771 
treatment diminished PrPC expression (Figure 5b) and PrPSc 
levels  (Figure  5c)  compared  to  PBS-infused  control  mice. 
PrPC expression was primarily reduced on the left side where 
ASO 771 was released from the tip of the cannula. As shown, 
PrPC was reduced in the substantia nigra, striatum, cerebral 
cortex,  hippocampus,  caudate  nucleus,  amygdala,  and  the 
periaqueductal region (Figure 5b). A less marked reduction 
was observed in the pons and cerebellum (data not shown). It 
appears that there is a pharmacologically significant gradient 
from the ipsilateral to contralateral side (Figure 5b, bottom 
row).
To examine in situ PrPSc deposition, PrPC was degraded by 
limited digestion with proteinase K followed by GdnHCl dena-
turation of PrP 27-30 before immunostaining (Figure 5c). In 
the brains of PBS-treated mice killed at 50 dpi, PrPSc deposits 
were visible in the white matter tracts (corpus callosum, stria-
tum), septum, hippocampus, and midbrain 1 and 2. The most 
intense immunostaining of PrPSc was seen in the thalamus 
at the site of inoculation. In the mice receiving ASO 771 and 
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studies. (a,d) Experimental design. ASOs were administered for 21 days at the specified doses, after which time, mice were killed, tis-
sues taken, and mRNA and protein levels were analyzed. (b,f) Prnp mRNA levels were measured by qRT-PCR; (c,g,h) PrPC levels were 
analyzed by a capture ELISA using antibody D18 (c) or by densitometry (g) of western blots probed with antibody D18 (h). (e) Brain map 
showing specific brain regions that were cannulated (region 3), harvested for protein (region 1), and RNA (region 2). (g,h) ASO 771 more 
effectively reduced PrPC levels in brain compared to ASO 742. Different lanes represent four different animals. Bottom panel of western 
blot was probed with actin. Protein standards shown are 36, 30, and 22 kilodaltons. For all panels, PrP expression levels are shown as 
percentages relative to those measured in mice treated with PBS. ELISA, enzyme-linked immunosorbent assay; ICV, intracerebral ven-
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ASO 923, PrPSc deposits were minimal, indicating that the 
ASO inhibited prion replication and propagation bilaterally.
Western immunoblotting of brain homogenates revealed 
that only ASO 771–treated FVB mice had decreased PrPC 
expression (Figure 5d, top proteinase K (PK)−), whereas 
both ASO 771 and ASO 923 treatment resulted in diminished 
signals for PrPSc (Figure 5d, bottom PK+, two different gels 
with different animals). Densitometry of western blots quanti-
fied a ~50% reduction of total PrP expression throughout the 
brains of ASO 771–treated mice compared to mice infused 
with  PBS  and  to  mice  treated  with  ASO  923  (Figure  5e, 
top). PrPSc   levels were reduced by 96% in ASO 771–treated 
mice and by 92% in ASO 923–treated mice (Figure 5e, bot-
tom). Although both sequence-specific ASO 771 and non–
sequence-  specific  ASO  923  reduced  PrPSc  levels  equally 
well in the brains of prion-inoculated mice at 50 dpi, only ASO 
771 reduced the PrPC substrate.
The  treated  mice  killed  at  126  dpi  showed  a  more 
advanced pathological deposition of PrPSc than those killed 
at 50 dpi described above. Histoblots of symptomatic con-
trol mice and asymptomatic ASO-treated mice at 126 dpi 
revealed abundant PrPSc in control mice but much less PrPSc 
in ASO-treated mice (Figure 6d). At the level of the septum 
(Bregma 0 mm), PrPSc was diminished in the frontal cerebral 
cortex and striatum/caudate nucleus on the side of the can-
nula. At the level of the hippocampus, the PrPSc signal was 
depressed bilaterally in the cerebral cortex, hippocampus, 
and amygdala. The ASO 771–treated mice killed at 126 dpi 
showed considerable PrPSc in the right thalamus where they 
had been inoculated with RML prions; they also harbored 
PrPSc deposits in the right corpus callosum. At the level of 
midbrain 1 (Bregma −2.92 mm), no PrPSc was detected in 
the  cerebral  cortex,  substantia  nigra,  ventral  hippocam-
pus,  or  periaquel  aquaduct.  In  the  brain  stem  (midbrain/
pons/medulla), PrPSc levels were reduced ~50% compared 
to  PBS-treated  mice  (Figure  6d).  Immunohistochemical 
staining for PrPSc showed more intense staining in the hip-
pocampus on the contralateral side of cannulation (data not 
shown).
In a survival study, six control, prion-inoculated mice that 
received  PBS  developed  neurological  dysfunction  with  a 
mean incubation period of 136 ± 4 days. Eight mice treated 
with ASO 771 had a mean incubation period of 193 ± 10 
days, representing a 40% prolongation in the incubation time 
(Figure 6b). One ASO-treated mouse exhibited signs of CNS 
dysfunction at 132 dpi while the other seven ASO-treated 
mice succumbed to disease between 183–228 dpi. ASO 771 
administration for 14 days substantially reduced PrPSc levels 
in prion-infected mice, even 112 days after treatment ceased 
(126 dpi) at the time of killing (Figure 6d). ASO-treated mice 
exhibited PrPC levels that were slightly lower than those found 
in PBS-treated, control mice at 126 dpi (see Figure 6c). A 
persistent, ASO-induced reduction in PrPC expression was 
observed in periventricular regions as well as the hippocam-
pus and cerebellum.
Delayed  infusion  of  ASO  771.  To  assess  the  effective-
ness of ASOs in mice with an established prion infection, 
we began infusing ASO 771 at 60 dpi. At this point in the 
incubation period, FVB mice remain asymptomatic but their 
brains show PrPSc accumulation as well as initial changes 
of astrocytic gliosis.11 Beginning 60 days after intracerebral 
inoculation with RML prions, the FVB mice received either 
75 µg/day of ASO 771 (n = 24) or PBS (n = 8) by ICV. While 
75 µg/day of ASO 771 was well-tolerated in uninfected FVB 
mice for 14 days, this dose was toxic in prion-infected mice, 
which had to be killed after 11 days. The toxicity of ASO 771 
appears to be related to the stage of prion disease because 
similar ICV infusion started 1 dpi was well-tolerated (com-
pare Figures 6 and 7). This illness was likely unrelated to 
prion disease. That the illness observed in prion-infected 
FVB mice at 11 days after ICV infusion was related to ASO 
771 is supported by the well-tolerated injection of PBS in 
control, infected mice that survived for 2 months following 
11–14 days of ICV infusion and developed signs of scrapie 
at 131 ± 1 days (n = 4).
The brains of ICV-infused mice were taken at 71 dpi and 
examined by immunohistochemistry to detect vacuolation 
and PrPSc plaque deposition (Figure 7b) as well as by histo-
blotting in order to measure PrPC and PrPSc (Figure 7c,d). In 
mice receiving PBS, PrPSc deposition was widely distributed 
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on both sides of the brain while those treated with ASO 
771 exhibited considerably less PrPSc. Notably, much of the 
PrPSc remaining after ASO infusion was found in plaque-like 
deposits along the corpus callosum (Figure 7b). Histoblots 
prepared  from  brains  of  ASO  771–treated  mice  showed 
bilateral reductions of PrPC in the septum, hippocampus, 
and midbrain 1 region, albeit with a greater suppression on 
the cannulated, left side (Figure 7c). PrPSc levels were also 
reduced bilaterally in the hippocampus, substantia nigra, 
ventral hippocampus, cerebral cortex, midbrain, and brain 
stem after treatment with ASO 771 (Figure 7d). PrPSc was 
cleared from the thalamus, amygdala, and caudate nucleus 
on the cannulated, left side, but persisted in the corpus cal-
losum and the thalamus on the contralateral right side. The 
control FVB mice receiving the PBS infusion and killed at 
71 dpi showed PrPC and PrPSc deposits throughout their 
brains.
Discussion
The  dual  action  of  ASO  771—(i)  specific  degradation  of 
Prnp mRNA and (ii) nonspecific reduction of PrPSc—com-
plicates any interpretation of the studies described here. 
The  PrP-specific  ASO  771  suppressed  PrPC  expression 
by binding to Prnp mRNA and rendering these transcripts 
susceptible to digestion by RNase H.10 Independent of the 
ASO  sequence,  these  PS-DNA  oligonucleotides  reduced 
PrPSc levels, as previously reported for ScN2a cells.5,6 The 
mechanism by which ASOs diminish PrPSc remains to be 
determined; it is unclear whether ASOs exert their antiprion 
action by inhibiting nascent PrPSc formation or accelerating 
PrPSc clearance. In ScN2a cells, the EC50 value for ASO 771 
in lowering PrPC levels was 50 nmol/l and in reducing PrPSc 
levels was 4 nmol/l. In earlier studies, the EC50 value for 
a CpG PS-DNA 22mer was 4,000 nmol/l for lowering PrPC 
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and was 70 nmol/l for reducing PrPSc.6 This 22mer was not 
selected for its Prnp mRNA-lowering activity but rather for 
its ability to prolong the incubation times of mice inoculated 
ip with RML prions.12
While  only  sequence-specific  ASOs  targeting  mouse 
Prnp  reduced  PrPC  levels,  both  sequence-specific  ASOs 
and  scrambled  ASO  923  cleared  PrPSc  in  ScN2a  cells 
(Figure  2b).  Dose-response  experiments  in  ScN2a  cells 
revealed that slightly higher concentrations of ASO 923 were 
required to reduce PrPSc levels compared to those found with 
sequence-specific ASO 771 (Figure 2d). In addition, longer 
treatment periods with ASO 923 were required to achieve 
the same level of knockdown as ASO 771 (Figure 2c). A 
similar sequence-independent reduction in PrPSc levels was 
observed in vivo (Figure 5d,e). Together, the results suggest 
that PrP-targeted, PS-modified ASOs can reduce brain prion 
levels by two independent mechanisms: reduction of Prnp 
mRNA and diminution of PrPSc. The in vivo studies with ASOs 
reported here argue that the reduction in PrPSc was greater 
than  the  diminution  in  PrPC;  however,  we  cannot  deduce 
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from our data the relative contribution of PrPC suppression to 
reducing the level of PrPSc.
The long tissue half-life of the ASOs (20–40 days in vivo) 
(ISIS unpublished data) and their ability to suppress PrPC 
and PrPSc expression for more than 100 days following can-
nula removal are noteworthy. When ASO 771 was admin-
istered immediately following prion inoculation for 14 days, 
PrPSc levels were reduced by 95% when measured 36 days 
after  removal  of  the  cannula  (Figure  5e).  Although  ASO 
771  administration  significantly  impeded  PrPSc  replication 
and extended survival times by almost 2 months, it did not 
eliminate PrPSc and the mice eventually succumbed to prion 
disease (Figure 6b). Interestingly, at 112 days after removal 
of the cannula, reduced levels of PrPC and PrPSc persisted, 
contending that ASO 771 was still present at sufficiently high 
concentrations to be biologically active (Figure 6c,d).
Intraventricular infusion of ASOs. ASOs dispensed directly 
into the ventricular system via the CSF of the lateral ven-
tricle have been previously reported to be an effective way 
to  achieve  widespread  delivery  throughout  the  brain  and 
penetrate the neural tissue of rodents, dogs, and non-human 
primates.13 Approximately half of the cannulated FVB mice 
died shortly after surgery—many of these deaths were due to 
hippocampal lesions resulting from accidental intraparenchy-
mal catheter implantation. These mice were excluded from 
the study as well as the incubation time calculations. Those 
brain regions near the tip of the cannula were exposed to the 
highest levels of ASO 771, and reductions in PrPC and PrPSc 
occurred up to distances of 5.88 mm Bregma.
ICV injection of ASO 771 through a cannula on the left side 
of the brain produced greater reductions of PrPSc than PrPC 
on the contralateral, right side where the prions were inocu-
lated into the thalamus (Figure 6c,d). The greater reduction 
in PrPSc levels compared to PrPC is readily explained by the 
sequence-independent,  ASO-mediated  diminution  in  PrPSc 
demonstrated in cultured cells (Figure 2d). Our findings are 
consistent with results from an earlier study reported by one 
of us (S.B.P.) where PS-DNA (22mers) containing a methy-
lated CpG motif (non-immune reactive) and scrambled CpG 
motifs equally diminished PrPSc levels in ScN2a cells, indicat-
ing a sequence-independent reduction of PrPSc.6 The EC50 
values for these 22mers were 5 µmol/l for PrPC and 70 nmol/l 
for PrPSc. Bioassays with treated cell extracts demonstrated 
that the prion titers were reduced in the PS-DNA–treated 
ScN2a cells.
In the work presented here, the EC50 value of the sequence-
specific ASO 771 was 100-fold lower for PrPC (50 nmol/l) 
reduction than previously reported for the CpG motif 22mers 
(5 µmol/l). In addition, we did not observe a significant reduc-
tion of PrPC with the scrambled ASO 923, arguing that the 
PrPC  reduction  we  observed  with  ASO  771  resulted  from 
degradation of the Prnp transcripts.
In  another  study,  a  series  of  random-sequence,  single-
stranded PS-DNA 40mers was added to ScN2a cells, result-
ing in diminished levels of PrPSc.5 When Tg(SHaPrP)7 mice 
were given daily ip doses of one random-sequence PS-DNAs 
beginning  3  days  before  ip  inoculation  with  SHa  prions, 
the incubation times were prolonged from 88 to 330 days. 
After prion inoculation, the Tg7 mice received ip injections 
of the random-sequence PS-DNAs three times per week for 
4 weeks. Since PS-DNAs administered ip did not traverse the 
blood-brain barrier, it is likely that the prolongation of incuba-
tion periods reported in these studies was due to systemic 
degradation of PrPSc outside of the CNS.
In the study described here, we intracerebrally inoculated 
RML prions into the right thalamus and 1 day later inserted a 
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cannula on the left side of the brain, through which we infused 
ASO 771 for 14 days. This ASO treatment protocol increased 
the incubation time from 136 to 193 days (Figure 6b). In the 
ASO 771–treated mice that were killed at 126 dpi, the PrPSc 
levels were reduced throughout the brain compared to the 
untreated controls, except in the right thalamus where both 
control and treated mice had been inoculated.
It is instructive to compare the prolongation of the incuba-
tion time by ICV infusion of ASO 771–treated mice with that 
of Prnp+/0 mice where PrPC levels were reduced ~50%. In 
both cases, the mice had diminished PrPC from very early 
in the incubation period. In studies by one of us (S.B.P.), 
Prnp+/0/FVB  mice  inoculated  with  RML  prions  developed 
CNS dysfunction between 400 and 465 days after intracere-
bral inoculation compared to wt mice exhibiting neurologic 
signs at 146 days.14 In another study, Prnp+/0 mice devel-
oped  CNS  dysfunction  between  260  and  350  days  after 
receiving RML prions ic.15 Recently, a third study using the 
same gene knockout showed signs of neurological disease 
between 240 and 300 days after intracerebral inoculation 
of RML prions.16 In the third study, prion titers were mea-
sured in the brains of Prnp+/0 mice using endpoint titrations 
in cultured cells. At 100 days after intracerebral inoculation, 
the brain titers were found to reach a maximum but more 
than another 150 days passed before signs of brain dys-
function were observed. The authors argued that an isoform 
other than PrPSc is neurotoxic and that this alternative form 
induces clinical signs. Whether infusions of ASOs can help 
decipher  the  molecular  pathogenesis  of  prion  disease  is 
unknown at present.
Concluding  remarks.  The  sequence-independent  inhibi-
tion of PrPSc formation complicated the interpretation of our 
findings using ASO 771. Delaying the infusion of ASOs until 
60  days  after  inoculation  resulted  in  many  acute  deaths 
 ( Figure 7), which prevented us from measuring the antiprion 
effect of these PS-modified oligonucleotides. We were also 
unable to lower substantially the PrPC levels throughout the 
brain after ICV infusion of ASO 771; whether this approach 
can be modified into an effective therapeutic regimen remains 
to be determined.
Materials and methods
ASO  synthesis.  Twelve  oligonucleotides  corresponding  to 
regions within the 3′ UTR were synthesized and purified as 
previously described.17 Oligonucleotides were PS-modified, 
chimeric oligonucleotides composed of five 2′-O-(2-methoxy)
ethyl modifications on both the 5′ and 3′ ends, and 10 oligo-
deoxynucleotides in the center to support RNase H   activity.18 
Oligonucleotide  sequences  were  as  follows:  ASO  742 
  (TATATTCTTATTGGCCCGGT), ASO 747 (GCCTATGCTAAG-
TTACATGT), and ASO 771 (CCAAGGGTCACACGGTAAGC). 
ASO  923  (CCTTCCCTGAAGGTTCCTCC)  was  used  as  a 
control oligonucleotide because it shares identical chemis-
try and length to the PrP-targeted ASOs, is not predicted to 
hybridize to any known human or rat genes, and was previ-
ously shown not to have detectable effects in tissue culture 
or in mouse models.19
Quantitative RT-PCR. Total RNA was isolated using an RNeasy 
Mini prep kit (QIAGEN, Valencia, CA) according to the man-
ufacturer’s protocol. We combined 5–10 ng total RNA with 
100 nmol/l of each of the gene-specific, dual-labeled probes, 
and forward and reverse primers in a buffered solution consist-
ing of 1× TaqMan Buffer A (Applied Biosystems, Foster City, 
CA), 5.5 mmol/l MgCl2, 200 mmol/l concentrations of each 
dNTP (Amersham Biosciences, Piscataway, NJ), 2 U RNase 
inhibitor, 0.625 U AmpliTaq Gold, and 6.25 U murine leuke-
mia virus reverse transcriptase. Except for dNTP solutions, 
all reagents above were obtained from Applied   Biosystems. 
Quantitative  RT-PCR  reactions  were  conducted  and  ana-
lyzed on an ABI Prism 7700 Sequence Detector (Applied 
Biosystems).  Glyceraldehyde  3-phosphate    dehydrogenase 
mRNA levels were used as an internal reference for normal-
ization  among  samples.  Primer  probe  set  sequences  for   
PrP were: forward, 5′-TCTGTGTCCCCCATAGGCTAA-3′; rev-
erse,  5′-AGAGCAACTGGTCTACTGTACATTTCC-3′;  probe, 
5′-CC  CCTGGCACTGATGGGCCC-3.
Cell culture. For b.END, N2a and GT1 lines, cells were grown 
in 6-cm dishes in minimal essential medium until attaining 
90–95% confluence. Cells were trypsinized and diluted ten-
fold into 60-mm plates containing 4 ml of minimal essential 
medium. On the following day, ASOs were added to the cells 
at various concentrations in their normal growth media and 
incubated for variable periods of time. For b.END cells, cells 
were washed once with PBS and were transfected using the 
lipofectamine transfection reagent (Invitrogen, Carlsbad, CA) 
using 3 µl lipofectin/1 ml Optimem/100 nmol/l ASO. The trans-
fection mix was removed after 4 hours and replaced with nor-
mal growth media. All incubations were performed at 37 °C. 
Cells were harvested in 0.5 ml cold lysis buffer (10 mmol/l 
Tris-HCl,  pH  8;  100  mmol/l  NaCl;  0.5%  NP-40;  and  0.5% 
deoxycholate). RNA was harvested at different time points; for 
b.END cells, RNA was harvested 24 hours after transfection.
Stock b.END and N2a cells were maintained in minimal 
essential medium. The cells were harvested using 4 ml of 
0.5% trypsin and plated in a 1:20 dilution, fed on day 4, and 
trypsinized again in a 1:3 dilution onto 10-cm plates on day 6. 
All media were supplemented with 10% fetal bovine serum, 
2 mmol/l Glutamax (GIBCO BRL, Carlsbad, CA), 100 units/
ml penicillin, and 100 units/ml streptomycin in a humidified 
37 °C incubator with 5% CO2.
Immunoblotting. Confluent 6-cm diameter plates (~4 × 106 
cells) were washed in PBS and then lysed by the addition of 
500 µl of lysis buffer. The nuclear pellet was removed, and 
the protein concentration was determined by bicinchoninic 
acid assay as recommended by the manufacturer (Pierce, 
Rockford, IL). Proteinase K was added (1:50, PK:total pro-
tein), and the lysate was incubated at 37 °C for 1 hour. The 
reaction was stopped by the addition of 2 mmol/l phenyl-
methanesulfonylfluoride. Insoluble material was precipitated 
by ultracentrifugation at 48,000g for 1 hour at 4 °C. The pel-
let was resuspended in loading buffer, boiled for 5 minutes, 
then run on a 15% Tris·HCl gel for western blot analysis 
by using D18 as the detection antibody. Capture enzyme-
linked immunosorbent assays with D18 were performed as 
previously described.20www.moleculartherapy.org
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Quantification of PrPC levels. PrPC and PrPSc levels were 
quantified by either enzyme-linked immunosorbent assay 
or  performing  densitometry  of  scanned  western  blots 
films  using  NIH  Image  J  software  and  expressed  as 
  percentages  relative  to  that  measured  in  cells  treated 
with PBS.
Inoculation  and  animal  studies.  All  animal  protocols  were 
approved by the University of California San Francisco Insti-
tutional  Animal  Care  and  Use  Committee  and  met  ethical 
standards  for  animal  experimentation.  Ip  inoculations  were 
performed in the abdomen. For therapeutic studies, FVB mice 
were anesthetized with isoflurane, then inoculated with 30 µl of 
mouse-adapted RML prions. Inocula were injected directly into 
the right thalamus. Mice were monitored thrice weekly. When 
they  showed  signs  of  prion  disease,  mice  were  euthanized. 
Brain cannulation and Alzet pump insertion in the subcutane-
ous pocket were performed on anesthetized animals.
Surgical placement of osmotic pumps and harvesting tissues 
for analysis. FVB mice weighing at least 20 g were placed in 
a chamber for the induction of anesthesia using 3–5% iso-
flurane in an air mixture. The animal was placed in a stereo-
taxic apparatus (Kopf 942, two-channel digital small animal 
stereotax; David Kopf Instruments, Tujunga, CA); a surgical 
plane of anesthesia was maintained with 2.5% isoflurane by 
a nose cone fitted to the stereotaxic instrument. A 1.5–2 cm 
midline incision was made in the scalp from the posterior of 
the occipital plate to the line connecting the eyes. A subcuta-
neous pocket measuring 5–6 cm deep was made with blunt 
dissection posterior from the incision over the left flank. The 
preloaded Alzet 2002 pump with tubing attached to the infu-
sion cannula was inserted pump-first into the subcutaneous 
pocket, leaving the cannula outside of the incision. The top 
tab of the infusion cannula was placed in a cannula-holding 
apparatus (Plastics One, Roanoke, VA). The tubing of the 
cannula was aligned with the hole in the skull and advanced 
into the hole until the base was against the skull. The incision 
was closed by sutures.
Histoblot. Histoblotting was performed as described pre-
viously.21  Coronal  cryosections  of  10-µm  thickness  were 
collected at the level of the septum (Bregma 0 mm). For 
prion-infected FVB mice, additional cryosections were taken 
from  the  hippocampus  (Bregma  −1.64  mm),  midbrain  1 
(Bregma −2.92 mm), midbrain 2 (Bregma −4.20 mm), pons 
(Bregma −5.46 mm), and cerebellum (Bregma −5.88 mm). 
Sections were placed on glass slides, then transferred to 
nitrocellulose membranes that were wetted in lysis buffer. 
Nitrocellulose strips were immersed in 100 mmol/l NaOH 
solution, incubated for 1 hour at room temperature, rinsed 
in  tris-buffered  saline  and  Tween-20  (TBST),  immersed 
again in 100 mmol/l NaOH solution, incubated for 1 hour 
at room temperature, rinsed in TBST, then immersed in 3 
mol/l guanidine isothiocyanate solution for 10 minutes at 
room temperature, and rinsed in TBST. Strips were blocked 
in 5% nonfat milk (made in TBST) for 30 minutes at room 
temperature, stained with the anti-PrP recombinant anti-
body  D18  followed  by  alkaline  phosphatase–conjugated, 
goat  anti-human  secondary  antibody  and  detection  with 
5-bromo-4-chloro-3-indolyl-phosphate/nitro  blue  tetrazo-
lium (BCIP/NBT).
Neuropathology.  Brains  were  removed  rapidly  from  eutha-
nized animals and either immersion-fixed in 10% buffered for-
malin or frozen on dry ice for neuropathological analysis. For 
evaluation of neurodegeneration, paraffin-embedded brains 
sections (8 µm) were stained with hematoxylin and eosin. For 
immunohistochemistry, PrPSc was detected on formalin-fixed, 
paraffin-embedded tissue sections by the hydrolytic autoclav-
ing method and with recFab HuM-P against PrP.22 For evalua-
tion of reactive astrocytic gliosis, we used a rabbit antiserum 
to glial fibrillary acidic protein (Dako, Carpinteria, CA) with 
peroxidase immunohistochemistry.23
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